Disease Landscape and Forecast Insights

The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilars developers must ensure that they are equipped with the necessary…

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity…

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…

Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…

Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

In 2019, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…

In 2019, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…

In 2019, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…